IL18 and inflammatory bowel disease: Importantly, neutralization of IL-18 with anti-IL-18 antibodies or IL-18BP is effective in both dextran sodium sulfate (DSS) and trinitrobenzoic sulfonic acid (TNSB)-induced models of IBD and reduces intestinal IFNγ and TNFα, demonstrating IL-18 as a pivotal mediator in experimental colitis (34, 36, 37).